← Back to Screener
Tenon Medical, Inc. Common Stock (TNON)
Price$0.82
Favorite Metrics
Price vs S&P 500 (26W)-36.60%
Price vs S&P 500 (4W)-8.40%
Market Capitalization$9.13M
All Metrics
Book Value / Share (Quarterly)$0.56
P/TBV (Annual)0.79x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)173.60%
Cash Flow / Share (Quarterly)$-1.32
Price vs S&P 500 (YTD)-17.66%
Gross Margin (TTM)52.40%
Net Profit Margin (TTM)-396.26%
EPS (TTM)$-2.76
10-Day Avg Trading Volume0.13M
EPS Excl Extra (TTM)$-2.76
Revenue Growth (5Y)130.83%
EPS (Annual)$-11.26
ROI (Annual)-228.99%
Gross Margin (Annual)52.21%
Net Profit Margin (5Y Avg)-1914.53%
Cash / Share (Quarterly)$0.40
Revenue Growth QoQ (YoY)32.24%
ROA (Last FY)-138.91%
Revenue Growth TTM (YoY)-2.47%
EBITD / Share (TTM)$-2.27
Operating Margin (TTM)-405.17%
Cash Flow / Share (Annual)$-3.21
P/B Ratio1.90x
P/B Ratio (Quarterly)2.12x
Net Income / Employee (Annual)$-1
EV / Revenue (TTM)1.76x
Net Interest Coverage (TTM)-110.29x
ROA (TTM)-114.60%
EPS Incl Extra (Annual)$-11.26
Current Ratio (Annual)4.39x
Quick Ratio (Quarterly)1.56x
3-Month Avg Trading Volume0.73M
52-Week Price Return-29.07%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.50
P/S Ratio (Annual)2.79x
Asset Turnover (Annual)0.33x
52-Week High$2.48
Operating Margin (5Y Avg)-1811.84%
EPS Excl Extra (Annual)$-11.26
26-Week Price Return-32.62%
Quick Ratio (Annual)3.96x
13-Week Price Return-15.16%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)2.15x
Enterprise Value$5.692
Revenue / Share Growth (5Y)127.19%
Asset Turnover (TTM)0.29x
Revenue / Employee (Annual)$0
Inventory Turnover (Annual)2.70x
Pretax Margin (Annual)-417.24%
Cash / Share (Annual)$2.08
3-Month Return Std Dev78.96%
Gross Margin (5Y Avg)29.12%
Net Income / Employee (TTM)$-0
ROE (Last FY)-228.99%
Net Interest Coverage (Annual)-509.86x
EPS Basic Excl Extra (Annual)$-11.26
Receivables Turnover (TTM)2.96x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-2.76
Receivables Turnover (Annual)4.75x
ROI (TTM)-190.80%
P/S Ratio (TTM)2.83x
Pretax Margin (5Y Avg)-1978.28%
Revenue / Share (Annual)$2.70
Tangible BV / Share (Annual)$5.56
Price vs S&P 500 (52W)-58.90%
Year-to-Date Return-15.02%
5-Day Price Return9.27%
EPS Normalized (Annual)$-11.26
ROA (5Y Avg)-156.48%
Net Profit Margin (Annual)-417.24%
Month-to-Date Return11.44%
Cash Flow / Share (TTM)$-13.87
EBITD / Share (Annual)$-11.05
Operating Margin (Annual)-420.08%
EPS Basic Excl Extra (TTM)$-2.76
P/TBV (Quarterly)2.36x
P/B Ratio (Annual)0.99x
Inventory Turnover (TTM)1.56x
Pretax Margin (TTM)-396.26%
Book Value / Share (Annual)$1.90
Price vs S&P 500 (13W)-15.85%
Beta1.41x
Revenue / Share (TTM)$0.39
ROE (TTM)-190.80%
52-Week Low$0.64
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.13
4.13
4.13
4.13
Industry Peers — Surgical & Medical Instruments(108)
| Symbol | P/S Ratio (TTM) | Revenue Growth (5Y) | Gross Margin (TTM) | Operating Margin (TTM) | Price |
|---|---|---|---|---|---|
TNONTenon Medical, Inc. Common Stock | 2.83x | 130.83% | 52.40% | -405.17% | $0.82 |
SYKStryker Corporation | 5.15x | 11.84% | 64.57% | 19.43% | $338.38 |
BSXBoston Scientific Corp. | 4.76x | 15.16% | 69.01% | 18.00% | $63.42 |
MMM3M Company | 3.18x | -4.97% | 39.92% | 18.55% | $150.55 |
MDLNMedline Inc. Class A common stock | 2.21x | — | 26.44% | 7.78% | $46.94 |
BDXBecton, Dickinson and Co. | 2.01x | 6.32% | 46.42% | 12.15% | $154.82 |
RMDResMed Inc. | 6.06x | 11.72% | 60.85% | 33.70% | $224.72 |
DXCMDexCom, Inc. | 5.23x | 19.33% | 62.09% | 19.56% | $61.23 |
WSTWest Pharmaceutical Services, Inc. | 6.22x | 7.44% | 35.91% | 19.03% | $269.81 |
PODDInsulet Corporation | 5.31x | 24.53% | 71.63% | 12.92% | $201.47 |
PENPenumbra, Inc. | 9.31x | 20.16% | 67.14% | 13.48% | $331.47 |
About
Tenon Medical develops minimally invasive solutions for treating sacroiliac joint disorders, a significant source of lower back pain. The company's Catamaran System—a single titanium implant—serves three market opportunities: primary procedures, revision surgeries, and spine fusion adjuncts. Currently, revenue is generated through sales to a limited number of clinicians, with potential for expansion as clinical adoption grows.